about
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.An esterase-activated magnetic resonance contrast agent.Luminescence study of Eu(III) analogues of esterase-activated magnetic resonance contrast agents.Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles.Nanomedicines for HIV therapy.Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs.Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields.Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems.Cell-permeable Ln(III) chelate-functionalized InP quantum dots as multimodal imaging agents.Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system.pH-responsive lanthanide complexes based on reversible ligation of a diphenylphosphinamide.Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensionsHigh-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coliReactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleachingFacile synthesis of complex multi-component organic and organic–magnetic inorganic nanocomposite particlesMulticomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems
P50
Q28821119-BDA79BCE-26C6-4A25-9C5B-52F7B93C7986Q31132081-1D42B294-038A-49B9-9C95-4D7B38CB0F36Q33498064-D877647B-714A-4C97-A6CE-ED119E5871EAQ40563147-45C7011C-F4E7-429C-805F-B95A7F655686Q44880910-A8D4964C-F4A3-49CF-8817-FAD9A48DD820Q46448056-D40878D7-7898-4FC5-BACD-3925051FBA65Q48337638-6869F622-F728-4815-BD39-F6AF8E6FBF19Q50967183-7F17C664-7A30-4685-82B3-04FDF77116ABQ51446743-3F51EF98-B5B8-4907-A2B9-83790D963647Q51739696-4D64E1B0-B007-40CA-A4D8-2E6AE86635B6Q51765543-2E6965BE-B4EA-4FB7-A98F-ACA51C921435Q53555823-D5A0E658-F3D6-4D8D-9901-C4ABB73393FBQ54492029-12A6CAA2-117A-4394-93CE-C0877D5CA51AQ58073502-185E1F7C-3778-4821-ADA3-F5FAEEE34C83Q58073593-319BB597-9228-4134-A1B9-FCDD65F6E89BQ58073624-EB8327DC-E4DB-446D-9891-6B5AC1BE9488Q58073653-0F44F0C3-666C-4369-8792-134B1609801CQ58073672-40E10F46-5061-4BD1-90B1-8863FAABDB68
P50
description
researcher ORCID ID = 0000-0003-0560-4711
@en
wetenschapper
@nl
name
Marco Giardiello
@ast
Marco Giardiello
@en
Marco Giardiello
@es
Marco Giardiello
@nl
type
label
Marco Giardiello
@ast
Marco Giardiello
@en
Marco Giardiello
@es
Marco Giardiello
@nl
prefLabel
Marco Giardiello
@ast
Marco Giardiello
@en
Marco Giardiello
@es
Marco Giardiello
@nl
P106
P21
P31
P496
0000-0003-0560-4711